Metastatic Triple-Negative Breast Cancer (mTNBC) Market Size
Market Size in USD Bn
CAGR5%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 5% |
| Market Concentration | Medium |
| Major Players | G1 Therapeutics, PharmAbcine/Merck, Roche/Genentech, Bristol Myers Squibb, AstraZeneca and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Metastatic Triple-Negative Breast Cancer (mTNBC) Market Analysis
The metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.57 Bn in 2024 and is expected to reach USD 2.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031. The increasing incidence of breast cancer worldwide and limited treatment options for mTNBC are major factors driving the growth of this market.